γ' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity.
Biomarkers
COVID-19
Disease progression
Fibrinogen
Respiratory distress syndrome
Journal
Blood cells, molecules & diseases
ISSN: 1096-0961
Titre abrégé: Blood Cells Mol Dis
Pays: United States
ID NLM: 9509932
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
02
03
2023
revised:
21
04
2023
accepted:
24
04
2023
medline:
15
5
2023
pubmed:
8
5
2023
entrez:
7
5
2023
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is characterized by a pro-inflammatory state associated with organ failure, thrombosis, and death. We investigated a novel inflammatory biomarker, γ' fibrinogen (GPF), in 103 hospitalized patients with COVID-19 and 19 healthy controls. We found significant associations between GPF levels and the severity of COVID-19 as judged by blood oxygen saturation (SpO
Identifiants
pubmed: 37150704
pii: S1079-9796(23)00023-2
doi: 10.1016/j.bcmd.2023.102746
pmc: PMC10147444
pii:
doi:
Substances chimiques
Fibrinogen
9001-32-5
Biomarkers
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102746Subventions
Organisme : NIGMS NIH HHS
ID : K23 GM130892
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest OHSU and David H. Farrell have a significant interest in Gamma Diagnostics, a company that may have a commercial interest in the results of this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU. Jamie Noll was the Chief Scientific Officer of Gamma Diagnostics, and Lucy Z. Kornblith is a scientific advisor to Gamma Diagnostics. None of the other authors declare any competing interests.